Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2015

01-04-2015 | Gastrointestinal Oncology

Port-Site Metastases is an Independent Prognostic Factor in Patients with Peritoneal Carcinomatosis

Authors: Maria F. Nunez, MD, Armando Sardi, MD, FACS, William Jimenez, MD, Carol Nieroda, MD, Michelle Sittig, RN, Ryan MacDonald, PhD, Nail Aydin, MD, Vladimir Milovanov, MD, Vadim Gushchin, MD, FACS

Published in: Annals of Surgical Oncology | Issue 4/2015

Login to get access

Abstract

Introduction

Port-site metastases (PSMs) have been reported after laparoscopy in patients with peritoneal carcinomatosis (PC). We hypothesize that PSM is an independent negative predicting factor of survival in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Methods

A retrospective review of a prospective database was conducted to search patients who underwent laparoscopy prior to CRS/HIPEC. Most of the tumors were of appendiceal origin. All previous laparoscopy port sites were excised regardless of macroscopic tumor involvement. Patients were divided into two groups: patients with PSM [PSM (+)] and patients without PSM [PSM (−)]. Overall survival (OS) was estimated by Kaplan–Meier curves and the log-rank test. Cox regression [hazard ratios (HRs) and 95 % confidence intervals (CIs)] was used to test for independent effects of the PSM (+) and the associated clinicopathological variables.

Results

Sixty-five patients had laparoscopy before CRS/HIPEC. One hundred and forty-four port-sites were resected; 41 (29 %) ports were positive for malignancy in a total of 22 (34 %) patients. Mean OS at 1, 3, and 5 years was 88, 66, and 63 %, respectively. Survival in patients with PSM was 73, 35, and 23 %, respectively, compared with 95, 82, and 82 %, respectively, in patients without PSM (p ≤ 0.001). Positive lymph nodes (LNs) were detected in 13/22 patients with PSM and 11/43 patients without PSM. Independent effects on survival shows an HR of 3.136, 95 % CI 1.150–8.549 (p = 0.026) for LN metastases, and an HR of 3.462, 95 % CI 1.198–10.006 (p = 0.022) in patients with positive PSM.

Conclusion

PSMs are common in patients with PC undergoing CRS/HIPEC and are independently associated with a worse prognosis. Resection of previous laparoscopy port sites is advocated in patients with PC to ensure complete cytoreduction.
Literature
1.
Elias D, Goere D, Dumont F, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50(2):332–340.CrossRefPubMed
2.
Elias DM, Ouellet JF. Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am. 2001;10(4):915–933, xi.PubMed
3.
Sommariva A, Pilati P, Rossi CR. Cyto-reductive surgery combined with hyperthermic intra-peritoneal chemotherapy for peritoneal surface malignancies: current treatment and results. Cancer Treat Rev. 2012;38(4):258–268.CrossRefPubMed
4.
Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69–76.CrossRefPubMed
5.
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456.CrossRefPubMed
6.
Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98(4):263–267.CrossRefPubMed
7.
Omohwo C, Nieroda CA, Studeman KD, et al. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology. J Am Coll Surg. 2009;209(3):308–312.CrossRefPubMed
8.
Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23(1):187–190.
9.
Valle M, Federici O, Garofalo A. Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin N Am. 2012;21(4):515–531.CrossRefPubMed
10.
Ouellette JR, Ko AS, Lefor AT. The physiologic effects of laparoscopy: applications in oncology. Cancer J. 2005;11(1):2–9.CrossRefPubMed
11.
12.
Ziprin P, Ridgway PF, Peck DH, Darzi AW. The theories and realities of port-site metastases: a critical appraisal. J Am Coll Surg. 2002;195(3):395–408.CrossRefPubMed
13.
Chua TC, Yan TD, Morris D, Sugarbaker PH. Port-site metastasis following laparoscopic surgery. Adv Laparosc. 2011.
14.
Ramirez PT, Wolf JK, Levenback C. Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol. 2003;91(1):179–189.CrossRefPubMed
15.
Shoup M, Brennan MF, Karpeh MS, Gillern SM, McMahon RL, Conlon KC. Port site metastasis after diagnostic laparoscopy for upper gastrointestinal tract malignancies: an uncommon entity. Ann Surg Oncol. 2002;9(7):632–636.CrossRefPubMed
16.
Velanovich V. The effects of staging laparoscopy on trocar site and peritoneal recurrence of pancreatic cancer. Surg Endosc. 2004;18(2):310–313.CrossRefPubMed
17.
Dijkum V, Nieveen EJ, de Wit LT, Obertop H, Gouma DJ. Port-site metastases following diagnostic laparoscopy. Br J Surg. 1996;83(12):1793–1794.CrossRef
18.
El Halabi H, Gushchin V, Francis J, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110–114.CrossRefPubMed
19.
20.
Zivanovic O, Sonoda Y, Diaz JP, et al. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol. 2008;111(3):431–437.CrossRefPubMed
21.
Zmora O, Weiss EG. Trocar site recurrence in laparoscopic surgery for colorectal cancer. Myth or real concern? Surg Oncol Clin N Am. 2001;10(3):625–638.PubMed
22.
Garofalo A, Valle M. Laparoscopy in the management of peritoneal carcinomatosis. Cancer J. 2009;15(3):190–195.CrossRefPubMed
23.
Neuhaus SJ, Texler M, Hewett PJ, Watson DI. Port-site metastases following laparoscopic surgery. Br J Surg. 1998;85(6):735–741.CrossRefPubMed
24.
Schaeff B, Paolucci V, Thomopoulos J. Port site recurrences after laparoscopic surgery: a review. Dig Surg. 1998;15(2):124–134.CrossRefPubMed
25.
Rao S, Rathod A, Kamble AT, Gupta D. Delayed presentation of port-site metastasis from an unknown gastrointestinal malignancy following laparoscopic cholecystectomy. Singapore Med J. 2014;55(5):e73–76.CrossRefPubMed
26.
Sommariva A, Zagonel V, Rossi CR. The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2012;19(12):3737–3744.CrossRefPubMed
27.
Halabi HE, Gushchin V, Francis J, et al. Prognostic significance of lymph node metastases in patients with high-grade appendiceal cancer. Ann Surg Oncol. 2012;19(1):122–125.CrossRefPubMed
28.
Van Sweringen HL, Hanseman DJ, Ahmad SA, Edwards MJ, Sussman JJ. Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surgery. 2012;152(4):617–624.CrossRefPubMed
29.
Maker AV, Butte JM, Oxenberg J, et al. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol. 2012;19(2):409–417.CrossRefPubMed
30.
Wu JS, Guo LW, Ruiz MB, Pfister SM, Connett JM, Fleshman JW. Excision of trocar sites reduces tumor implantation in an animal model. Dis Colon Rectum. 1998;41(9):1107–1111.CrossRefPubMed
31.
Muntean V, Oniu T, Lungoci C, et al. Staging laparoscopy in digestive cancers. J Gastrointestin Liver Dis. 2009;18(4):461–467.PubMed
32.
Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(5):540–543.CrossRefPubMed
33.
Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol. 2006;32(6):625–627.CrossRefPubMed
34.
Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg. 2013;100(2):285–292.CrossRefPubMed
Metadata
Title
Port-Site Metastases is an Independent Prognostic Factor in Patients with Peritoneal Carcinomatosis
Authors
Maria F. Nunez, MD
Armando Sardi, MD, FACS
William Jimenez, MD
Carol Nieroda, MD
Michelle Sittig, RN
Ryan MacDonald, PhD
Nail Aydin, MD
Vladimir Milovanov, MD
Vadim Gushchin, MD, FACS
Publication date
01-04-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 4/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4136-1

Other articles of this Issue 4/2015

Annals of Surgical Oncology 4/2015 Go to the issue

Breast Oncology

The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients

Urologic Oncology

High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer

Breast Oncology

Papillomas of the Breast 15 mm or Smaller: 4-Year Experience in a Community-Based Dedicated Breast Imaging Clinic

Head and Neck Oncology

Surgeon-Performed Ultrasound-Guided Fine-Needle Aspiration Cytology of Head and Neck Mass Lesions: Sampling Adequacy and Diagnostic Accuracy

Endocrine Tumors

Navigating the Management of Follicular Variant Papillary Thyroid Carcinoma Subtypes: A Classic PTC Comparison

Endocrine Tumors

CaPTHUS Scoring Model in Primary Hyperparathyroidism: Can It Eliminate the Need for ioPTH Testing?